Foundayo Pricing: October 2026

Foundayo self-pay prices held steady into October, and TrumpRx now lists them. Foundayo (orforglipron) is Eli Lilly's once-daily GLP-1 pill, approved April 1, 2026 for weight management, and its wholesale acquisition cost (WAC), the list price, is $649 a month, although few people pay that. As of October 5, 2026, LillyDirect charges $149 a month for the 0.8 mg starting dose, $149 for 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg. The 14.5 mg and 17.2 mg doses are $299 when refilled within 45 days under the Self-Pay Journey Program and $349 after a missed refill. The 2.5 mg and 5.5 mg prices are temporary cuts through December 31, 2026, after which TrumpRx shows them returning to $199 and $299.

All three big PBMs cover it, but employers are pulling back on weight-loss drugs. A pharmacy benefit manager (PBM) builds the drug list, called a formulary, for employer health plans, and Foundayo is on all three of the largest ones: Express Scripts and OptumRx from launch, and CVS Caremark since June 1, 2026. With commercial coverage, Lilly's savings card brings the copay to as little as $25 a month. Employers still decide whether to cover obesity drugs at all, though. PepsiCo ended its coverage in October, and a Mercer survey found about 6% of large employers dropped weight-loss drugs in 2026, with another 5% planning to in 2027.

Medicare covers the pill through the Bridge, while some Medicaid programs have dropped it. The Medicare GLP-1 Bridge launched July 1, 2026, and eligible Part D members pay $50 a month for any Foundayo strength, with a prior authorization (an approval request) filed by their prescriber. The program runs through December 31, 2027, and the $50 copay does not count toward the Part D deductible. On the Medicaid side, Rhode Island stopped covering Foundayo, Wegovy, Zepbound, and Saxenda for weight loss on October 1, 2026. TrumpRx.gov now shows Foundayo prices dose by dose, matching LillyDirect, and sends buyers there to fill the prescription.

The launch is gaining ground on the Wegovy pill. Lilly reported $98 million in Foundayo sales for the second quarter on August 5, 2026, its first full quarter, while Novo Nordisk's Wegovy pill did $496 million. On September 14, a Lilly executive said Foundayo had captured more than 30% of new U.S. patients starting an oral obesity drug. Foundayo is still approved only for weight management. Lilly's ACHIEVE-4 trial in type 2 diabetes, presented October 1, 2026, found it noninferior to insulin glargine on heart events, but that does not make it a diabetes drug on the label yet.

For the head-to-head, see Foundayo vs. Oral Wegovy. For Lilly's injectable, see Zepbound Pricing. For Medicare rules in detail, see the Medicare GLP-1 Bridge Pricing Guide. For the whole class, see the GLP-1 Drug Pricing Guide: September 2026.

Updated October 5, 2026: Rechecked every price. Self-pay prices did not change since September 2. Added TrumpRx's dose-by-dose prices and the $349 price after a missed refill for the top two doses, the post-December regular prices for 2.5 mg and 5.5 mg, PepsiCo's coverage cut and the Mercer employer survey, Rhode Island Medicaid's October 1 change, and Lilly's September 14 share figure. Removed the September note that TrumpRx showed no Foundayo price.